Journal
NATURE MEDICINE
Volume 28, Issue 2, Pages 303-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41591-022-01688-4
Keywords
-
Funding
- European Union [HEALTH-F4-2012-305312]
- Metagenopolis grant [ANR-11-DPBS-0001]
- Leducq Foundation,
- Novo Nordisk Foundation
- NIHR Imperial Biomedical Research Centre
- French National Research Agency [ANR-10-LABX-46]
- French National Agency for Research [ANR-18-IBHU-0001]
- European Union (FEDER)
- Hauts-de-France Regional Council [20001891/NP0025517, 20002845]
- European Metropolis of Lille [2019_ESR_11]
- ANR [ANR-16-IDEX-0004-ULNE]
- European Metropolis of Lille
- Medical Research Council Skills Development Fellowship [MR/S020039/1]
- Wellcome Trust [204834/Z/16/Z]
- Medical Research Council Intermediate Research Fellowship in Data Science (UK Med-Bio) [MR/L01632X/1]
- German Centre for Cardiovascular Research
- German Research Council [SFB1365, SFB1470, KFO339]
- German Ministry of Education and Research
- National Center for Precision Diabetic Medicine
- Wellcome Trust [204834/Z/16/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
This study investigates the alterations of the metabolome and microbiome from dysmetabolic conditions to ischemic heart disease (IHD). The findings suggest that major changes in the gut microbiome and metabolome may occur long before the clinical onset of IHD. Specific microbiome and metabolome features associated with IHD could better differentiate individuals with IHD from healthy individuals, indicating their pathophysiological relevance.
By studying individuals along a spectrum of cardiometabolic disease and adjusting for effects of lifestyle and medication, this investigation identifies alterations of the metabolome and microbiome from dysmetabolic conditions, such as obesity and type 2 diabetes, to ischemic heart disease. Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages-acute coronary syndrome, chronic IHD and IHD with heart failure-and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available